Session Information
Session Type: Abstract Submissions (ACR)
Background/Purpose:
Inreased ferritin levels are protective during infection whereas but very very high level are associated with MAS in rheumatologic disease cTo determine frequency of macrophage activation syndrome (MAS) in a sepsis cohort defined by using ferritin level (> 2,000), and to compare outcome, organ involvement and response to anakinra in sepsis across levels of Ferritinemia.
Methods:
Remaining sera and data from “interleukin-1 receptor antagonist trial in severe sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial” (Opal, et. al. Crit Care Med. 1997 Jul;25(7):1115-24.) was analysed. Ferritin was measured in the remaining sera of de-identified subjects from this study (levels beyond 6,000 were not further diluted). Subgroups were defined based on serum ferritin ranges (0-499, 500-999, 1000-1999, above 2000 μg/L). Post hoc statistical analysis included: descriptive statistics, rank test, ANOVA, Cox regression.
Results:
Sera and data were available for ferritin measurement in 120/756 original study cohort (ages 22-85; 41.6% women). Demographics and 28-day outcome with or without anakinra in the ferritin subgroups are shown in Table. The Ferritin subgroup 500-999 had higher 28 day survival than other subgroups (18/21, 85.7%)(p < .05?), which was decreased with anakinra (100% alive in placebo vs. 82.4% with anakinra). The Ferritin subgroup >2000 (24/29, 24.2%) showed lower 28-day survival, which was increased with anakinra (40% with placebo vs. 57.9% with anakinra).
Conclusion:
As hypothesized, an increased Ferritin 500-1000 showed a protective inflammatory response in adult severe sepsis patients, whereasvery high Ferritin levels > 2,000 μg/L may signify immune dysregulation and concurrent MAS ( 25% of adult severe sepsis patients). Given the high mortality of unrecognized MAS in adults with rheumatic diseases (up to 64% reported) further stuies are warranted both evaluating ferritin in the diagnosis of, and anakinra in the treatment of severe sepsis associated MAS (Ferritin > 2,000)
Ferritin Range |
Group N (%) (Total 120) |
Age Range |
Woman (%) |
28 Day Alive |
28 Day Alive |
|
Anakinra |
Placebo |
|||||
0-499 |
42 (35.0) |
25-85 |
18/42 (42.9) |
27 (64.3) |
17/27 (62.9) |
10/15 (67.7) |
500-999 |
21 (17.5) |
22-83 |
7/21 (33.3) |
18 (85.7) |
14/17 (82.4) |
4/4 (100) |
1000-1999 |
28 (23.3) |
22-81 |
15/28 (53.6) |
18 (64.3) |
16/25 (64.0) |
2/3 (67.7) |
>2000 |
29 (24.2) |
28-76 |
10/29 (34.5) |
15 (51.8) |
11/19 (57.9) |
4/10 (40) |
Disclosure:
B. Shakoory,
None;
J. A. Carcillo,
None;
S. Opal,
None.
« Back to 2013 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/hyper-ferritinemia-suggests-a-high-frequency-of-macrophage-activation-syndrome-in-a-large-adult-severe-sepsis-cohort-a-role-for-anakinra/